Hi Everyone This is Lakshmi from EQ Pick. Let talk about Supriya Lifescience IPO closing tomorrow, As per my view there is nothing to lose in this IPO . Key point is Increasing exposure to high-margin regulated markets will support operating margins, while its backward integration plans augur well for the company Highlights - Dominant share in export of key APIs from India - Benefits from both China-plus and Aatmanirbhar themes - Investing in capacity & effluent treatment to meet medium-term demand - Key risks to monitor are product concentration & margin sustainability - Valuations reasonable; subscribe only with a long-term view ------------------------------ ------------------------- One thing that the ongoing pandemic has laid bare is the elevated supply-chain risk of dependence on China to manufacture APIs/drugs. This has led to various domestic and global initiatives to reduce this dependence and de-risk the pharma supply chain. The initial public offering (IPO) of Sup...